Advisory Alpha’s Editas Medicine EDIT Stock Holding History

Advisory Alpha’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-100	Closed	-$3K	–	245
2020 Q3	$3K	Buy	+100	New	+$3.26K	﹤0.01%	571
2020 Q2	–	Sell	-100	Closed	-$2.4K	–	220
2020 Q1	$2.4K	Hold	100	–	–	﹤0.01%	585
2019 Q4	$3.12K	Hold	100	–	–	﹤0.01%	633
2019 Q3	$1.99K	Buy	+100	New	+$2.48K	﹤0.01%	649
2019 Q2	–	Sell	-100	Closed	-$2.46K	–	252
2019 Q1	$2.46K	Buy	+100	New	+$2.26K	﹤0.01%	536

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Advisory Alpha's EDIT Position: Q4 2020 in Review

Advisory Alpha sold out of Editas Medicine (EDIT) in Q4 2020, closing a stake of 100 shares — an estimated $3K sold.

Advisory Alpha first reported a position in EDIT in Q1 2019 and held it in 5 quarters. The position peaked at $3.12K in Q4 2019. 311 funds tracked by Wall St. Rank hold EDIT as of Q4 2020.

Advisory Alpha reported no remaining Editas Medicine position as of Q4 2020 after selling out during the quarter.
Advisory Alpha sold 100 Editas Medicine shares in Q4 2020, an estimated $3K.
Advisory Alpha first reported a position in Editas Medicine in Q1 2019 and held it in 5 quarters.
Advisory Alpha's Editas Medicine position peaked at $3.12K in Q4 2019.
311 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2020.

Based on Advisory Alpha's 13F filing for Q4 2020, filed 16 Feb 2021.